ArticleCancer medicine2026
A Comparative Analysis of Multiple Myeloma Disease Burden in China and Globally From 1990 to 2023 and Future Trend Projections.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiple myeloma (MM) is a prevalent hematologic malignancy. A systematic comparison of the temporal trends in MM disease burden between China and the global level is important for optimizing prevention and control strategies. This study describes trends in the age- and sex-specific burden of MM in China from 1990 to 2023, including incidence, prevalence, mortality, and disability-adjusted life years (DALYs); projects sex-specific incidence to 2050; and compares findings globally.
methodsUsing the Global Burden of Disease (GBD) 2023 database, we extracted data on MM in China and globally from 1990 to 2023. Joinpoint regression was used to calculate the average annual percentage change (AAPC) and its 95% confidence interval (CI) for trend analysis, with comprehensive comparisons by age and sex. In addition, Bayesian age-period-cohort (BAPC) modeling was used to describe and predict sex-specific trends in MM incidence through 2050, with 95% uncertainty intervals (UIs) reported for GBD estimates and BAPC projections.
resultsFrom 1990 to 2023, the age-standardized incidence rate (ASIR) of MM increased from 0.30 to 0.94 per 100,000 people in China, and the global ASIR increased from 1.59 to 1.95 per 100,000. In China, the AAPC was 3.70%, well above the global level of 0.65%. Comparable differences were observed in prevalence, mortality, and DALYs. The burden of disease increased substantially with advancing age and was higher in males. The BAPC model suggested that by 2050, the ASIR for females in China may surpass that for males, whereas the global ASIR for both sexes is projected to continue to rise.
conclusionThe disease burden of MM in China has risen substantially faster than the global average over the past three decades and is expected to continue increasing, particularly among females. Priority public health strategies for prevention and control are essential to address this growing public health issue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.